Bridgewater, NJ (USA), November 28, 2017 – Amneal Biosciences has launched clofarabine injection, an AP-rated generic equivalent for Clolar®, in 1 mg/mL strength.  The product is supplied in a single-dose vial containing 20 mg of clofarabine in 20 mL of clear sterile solution and is latex and preservative free.  Clofarabine is available through wholesalers, distributors and direct to the trade.

“We are pleased to expand our product portfolio with clofarabine,” states Amneal Biosciences president Charles Lucarelli. “It’s an important addition to our growing oncology line.”

Annual U.S. sales of Clolar® were $53 million based on September 2017 IQVIA (formerly QuintilesIMS) market data.

Click here for more information, including full prescribing information for clofarabine injection.


About Amneal

Amneal Biosciences, a wholly-owned subsidiary of Amneal Pharmaceuticals LLC, is dedicated to the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics, anti-infectives and support care for healthcare providers and patients of all ages. The company’s expertise and focus on the unique needs and logistics of this market ensure the same level of quality and service for healthcare institutions and professionals that Amneal delivers to its retail customers.

Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in North America, Asia and Europe, working together to bring high-quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.  For more information, visit

All trademarks listed in this release are property of their respective owners.





John Niemi (sales)

Vice President, Sales

Amneal Biosciences